Question special

It was noted in the trial that there was not a significant improvement with regard to lung function endpoints such as FEV1 with mepolizumab.
If lung function is not impacted, what is the mechanism of the reduction in COPD exacerbations with mepolizumab? Does it all have to do with reduced inflammation?